Mount Sinai Health System has begun implementing a cloud-native platform that will integrate global cancer insights and use artificial intelligence to streamline pathology processes.
It's working with the genomic technology firm Sophia Genetics.
The Sophia DDM platform analyzes complex genomic and multimodal data like a multilayered AI pipeline.
It offers Mount Sinai faster cancer testing results, greater efficiency and "deeper genomic understanding to help shape the future of precision oncology," John Carey, Sophia Genetics managing director of North America, said in a statement.
With AI-powered analytics, Mount Sinai's molecular pathology teams can tap into an intelligence network of 800 global institutions through the decentralized architecture and interpret genomic variants based on data patterns seen across the world.
The health system said it is reducing bottlenecks in pathology workflows and, thus, improving patient care.
【MORE】